Quarterly report pursuant to Section 13 or 15(d)

6. Stockholders' Equity (Details Narrative)

v3.8.0.1
6. Stockholders' Equity (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Debt and Equity Financing [Member]    
Warrants outstanding 3,522,225  
Warrants weighted average exercise price $ 4.30  
Series B Preferred Stock [Member]    
Conversion of stock, shares converted   120,000
Common Stock [Member]    
Conversion of stock, shares issued   120,000
Pharmsynthez [Member]    
Debt converted, shares issued 125,397  
Debt converted, amount converted $ 500,000